CinCor Pharma
Clinical-stage biopharmaceutical company developing baxdrostat (CIN-107), a highly selective aldosterone synthase inhibitor for the treatment of hypertension and other cardiovascular conditions.
Website
https://www.cincor.comLocation
Waltham, Massachusetts, USA
Founded
2018
Investors
1
Categories
biotech, pharmaceuticals, cardiovascular, hypertension, therapeutics
Notes
CinCor Pharma (NASDAQ: CINC) is a clinical-stage biopharmaceutical company focused on developing treatments for cardiovascular diseases. The company's lead candidate, baxdrostat (CIN-107), is a highly selective aldosterone synthase inhibitor (ASI) being developed for treatment-resistant hypertension and other cardiovascular conditions.
In February 2023, AstraZeneca announced plans to acquire CinCor Pharma for $1.8 billion to expand its cardiovascular portfolio.
Team
- Marc de Garidel - Chairman & Chief Executive Officer
- LinkedIn: linkedin.com/in/marcdegaridel
- Joseph Gordon - Chief Financial Officer
Additional Research Findings
- NASDAQ: CINC (publicly traded, acquired by AstraZeneca)
- AstraZeneca acquisition announced February 2023 for $1.8 billion
- Lead candidate: baxdrostat (CIN-107) aldosterone synthase inhibitor
- Focus on treatment-resistant hypertension
- Portfolio company of Sofinnova Partners
- Headquarters in Waltham, Massachusetts
- Addressing unmet need in cardiovascular disease
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Sofinnova Partners | Paris, France | biotech-focused | seedseries-a+3 | 23 |